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Editorial
GRADE the evidence
Lisa A Harvey
Rehabilitation Studies Unit, Sydney School of Medicine/Northern, The University of Sydney, Australia
Systematic reviews and clinical practice guidelines 
are needed to inform and guide clinical practice in 
physiotherapy. Clinical practice guidelines should be 
based on systematic reviews, and both systematic reviews 
and clinical practice guidelines should rate the quality of 
evidence. However, only clinical practice guidelines should 
make direct recommendations about clinical practice 
because recommendations depend on information and 
judgements that go beyond systematic reviews (Guyatt et 
al 2008a).
Many systematic reviews and clinical practice guidelines 
rate the strength of evidence primarily on the basis of study 
design, risk of bias, and reported p values. For example, 
evidence from randomised controlled trials that report 
statistically signiﬁcant ﬁndings is rated highly. Similarly, 
randomised controlled trials that conceal allocation, blind 
assessors, and minimise drop outs are rated higher than 
trials that do not. This approach ignores many important 
aspects of evidence that need to be taken into account when 
rating its quality. For example, it ignores how conﬁdent 
we are in an estimate of the effect of a therapy and the 
relative importance of different types of outcomes to 
people who seek physiotherapy interventions. In addition, 
a sole focus on p values ignores imprecision which should 
be used to downgrade the quality of evidence and ignores 
other factors that can either decrease or increase our 
conﬁdence in estimates of effect. Given the abundance 
of systematic reviews and the growing number of clinical 
practice guidelines, it is perhaps now appropriate that 
the international physiotherapy community focuses on 
improving the way we rate evidence in our reviews and 
guidelines.
One way to improve the way we rate evidence in our 
systematic reviews and clinical practice guidelines is to fall 
in line with organisations such as BMJ Group, the Cochrane 
Collaboration, the American College of Physicians and 
the World Health Organisation, and use the GRADE 
system (Guyatt et al 2008a, Guyatt et al 2008b, Guyatt et 
al 2008c). The GRADE system (an acronym for Grading 
of Recommendations Assessment, Development and 
Evaluation) was ﬁrst published in 2004. It requires authors 
to initially identify outcomes that are of key importance to 
patients and discourages authors from relying on surrogate 
outcomes. The evidence supporting the effectiveness of an 
intervention on an outcome is then rated on a 4-point scale 
ranging from ‘very low’ to ‘high’.
Notably, evidence about the effectiveness of interventions 
on each outcome is not just rated according to study design 
or p values, although these are considered. Instead, evidence 
is also rated according to a number of factors. These include 
ﬁve factors that can lower our conﬁdence in estimates of 
effect (risk of bias, inconsistency of results across studies, 
indirectness of the evidence, imprecision of estimates, and 
publication bias) and three factors that can increase our 
conﬁdence (large effects, a dose response relationship, and 
effects that are opposite to what would be expected from 
the inﬂuences of confounding and bias). Freely available 
software (GRADEpro) can guide authors through each of 
these judgements. Some judgements are easier and less 
ambiguous to make than others. However, all important 
factors that inﬂuence our conﬁdence in estimates of the 
effect of an intervention are taken into account when rating 
the strength of the evidence.
Two key factors taken into account by the GRADE system 
are the size and precision of estimates. The precision of 
estimates is reﬂected in the width of conﬁdence intervals 
and tells us how conﬁdent we can be in an estimate. Quality 
of evidence should be downgraded if the width of the 
conﬁdence interval for an estimate of treatment effect is large 
and if the conﬁdence interval crosses a decision threshold 
(Guyatt et al 2011a). Similarly, the size of treatment effects 
is an important consideration. Observational studies that 
indicate very large treatment effects can provide moderate 
or even high quality evidence for an intervention. Although 
observational studies often overestimate treatment effects 
due to confounding, this alone cannot explain very large 
treatment effects (Guyatt et al 2011b). Consideration 
of the size and precision of estimates requires moving 
beyond p values, which may be misleading and are often 
misinterpreted (Goodman 1999). There are of course many 
other subtleties involved in using the GRADE system to 
rate the quality of evidence and readers are referred to the 
many excellent, freely available resources (eg, see Guyatt et 
al 2008a, Guyatt et al 2008b, Guyatt et al 2008c, Guyatt et 
al 2011c).
As the international physiotherapy community moves 
forward and continues to advocate for evidence-based 
care, we should be encouraging authors of systematic 
reviews and clinical practice guidelines to use the GRADE 
system to rate the quality of evidence in their systematic 
reviews and clinical practice guidelines, and the strength 
of recommendations in guidelines. Importantly, we should 
be encouraging better reporting of original comparative 
research to help authors of reviews and clinical practice 
guidelines adopt the GRADE system. For example, authors 
of original research need to clearly articulate, where 
appropriate, mean between-group differences and 95% 
CIs for continuous data, and risk ratios and 95% CIs for 
dichotomous data. Journal of Physiotherapy will continue 
to advocate for the adoption of GRADE and better reporting 
of comparative research in its efforts to help advance 
evidence-based physiotherapy.
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